Please assess the completion status of the following clinical trial:

Trial Title: Tipifarnib and Etoposide in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults age with established, pathologically confirmed diagnoses of newly diagnosed AML, including de novo and secondary AMLs but excluding newly diagnosed acute progranulocytic leukemia (APL, M3), will be considered eligible for study~* ECOG performance status 0-2~* Patient must be able to give informed consent~* Serum creatinine =\< 2.0 mg/dl~* SGOT and SGPT =\< 5 x upper limit normal (ULN)~* Bilirubin =\< 2 mg/dl~* Disease-specific criteria:~  * Newly diagnosed AML, subtypes M0,1,2,4-7 but excluding M3 (APL), including myelodysplasia (MDS)-related AML (MDS/AML) and treatment-related AML~ * Patients who have received hydroxyurea alone or have received non-cytotoxic therapies previously for MDS (e.g., thalidomide, interferon, cytokines, 5-azacytidine) will be eligible for this trial~Exclusion Criteria:~* Any previous treatment with R115777 or VP-16~* Patients receiving concomitant chemotherapy, radiation therapy or immunotherapy~* Hyperleukocytosis with \>= 30,000 blasts/uL or rapidly rising blast count with projected doubling time of =\< 2 days~* Acute progranulocytic leukemia (APL,M3)~* Active CNS leukemia~* Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible~* Presence of other life-threatening illness~* Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol~* Patients on enzyme-inducing anti-convulsants (e.g., phenytoin, fosphenytoin, phenobarbital, primidone, carbamazepine, oxcarbazepine); patients may be changed to non-enzyme inducing anti-convulsants and stabilized before starting study treatment

- Gender: ALL
- Minimum Age: 70 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (tipifarnib, etoposide) (Type: EXPERIMENTAL): Patients receive oral tipifarnib twice daily on days 1-14 OR 1-21 and oral etoposide once daily on days 1-3 and 8-10. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients who achieve a CR may receive up to 5 additional courses of therapy beyond documentation of CR.~Cohorts of 3-6 patients receive escalating doses of tipifarnib and etoposide until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Up to 14 additional patients receive treatment at the MTD.

Based on this trial design, predict the completion outcome and termination type (if applicable).